Registration Now Open for Ingram Micro’s Global ONE Experience – Join Us November 4-5 Online for an Unforgettable Event
7.10.2020 18:30:00 EEST | Business Wire | Press release
For the first time in its history, Ingram Micro Inc. is taking its ONE event to a fully global audience in a completely online interactive experience. Bringing together APAC ONE, EMEA ONE, LATAM ONE and North America ONE enable Ingram Micro to support multiple time zones and languages, while hosting 12 keynotes, 150 sessions and speakers and attendees from more than 60 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201007005717/en/
“We’ve set high expectations, and are excited to have our partners and providers take what they hear, see and experience at ONE and imagine what’s next for their business, their partner ecosystem and their customers." Paul Bay, EVP and President, Global Technology Solutions, Ingram Micro Inc. (Graphic: Business Wire)
As part of the experience, localized content and sessions will be provided for each region. Targeted sessions will also be held pre- and post-experience for special guests attending by countries and communities including Ingram Micro’s SMB Alliance and Trust X Alliance. Ingram Micro channel partners and providers are encouraged to register now at https://imaginenext.ingrammicro.com/one.
Ingram Micro’s executive leadership team will kick off this year’s online experience starting with opening remarks from CEO Alain Monié and EVP and President Paul Bay. Additional event highlights include:
- Fireside chats with Cisco CEO Chuck Robbins and IBM President Jim Whitehurst
- Futurist keynote featuring 311 Institute Founder and CEO Matthew Griffin
- Diversity and Inclusion Keynote from Former NASA Space Science Education Lead Hakeem Oluseyi
- Technology and trends keynote from IDC Group Vice President Michelle Bailey
- Executive addresses from global business leaders including Ingram Micro’s SVP of Marketing Jennifer Anaya, EVP Global Cloud Nimesh Davé, and VP of Global Partner Engagement and IoT Sabine Howest
- Special guests including a GRAMMY award winning musician and bands from around the globe
- An inspired address from one of the best-selling authors, and optimistic motivational speakers on the planet
A complete list of speakers and sessions, including the identities of the above artists and motivational speaker, is noted here. Additionally, several key Ingram Micro announcements and strategic initiatives are expected to launch leading up to and throughout the event, including community announcements from SMB Alliance and Trust X Alliance. Live networking, virtual happy hours and AI-powered business matchups are also on tap for attendees.
“We’ve set high expectations, and are excited to have our partners and providers take what they hear, see and experience at ONE and imagine what’s next for their business, their partner ecosystem and their customers,” said Bay. “Together we are working smarter, harder and with a greater purpose. Ingram Micro and the ecosystem of partner excellence we support has never been more relevant to the vitality and success of today’s business landscape locally, regionally and globally…and we’re ready to do even more.”
Channel press and analysts are welcome to register and attend designated sessions of the Nov. 4-5 Ingram Micro ONE Experience.
For more information visit https://imaginenext.ingrammicro.com/one.
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005717/en/
Contact information
Marie Rourke
WhiteFox Marketing
714.292.2199
marie@whitefoxpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom